CD8A and colitis: Corticosteroids, with their inhibiting properties on innate and adaptive immunity, represent the first line of therapy in ICI Colitis, especially from grade 2 upwards.33 They also appear to enhance the expression of PD-1 on CD4 and CD8 lymphocytes, reducing the activity of these cells.93 However, prolonged and high-dose administration of CS increases the risk of complications such as impaired glucose tolerance, infections, and altered bone metabolism.94 Furthermore, the impact of CS activity on reducing the anticancer effects of ICI is still unclear.